Announcements Trials
Browse Landscape

Phase

Phase 2 27Phase 3 10Phase 1 9Phase NA 7Phase 1/2 7Phase 2/3 2Phase 4 1

Status

Recruiting 6Unknown 3Completed 3Terminated 2Not yet recruiting 1Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1Gynecologic 1

Conditions

Overweight 1Obesity 1Neoplasms 1Endometrial Neoplasms 1Endometrial Hyperplasia 1

Interventions

Carboplatin 6anlotinib 5lenvatinib 4Oxaliplatin 4Immune Checkpoint Inhibitors 4Cisplatin 4tislelizumab 3sintilimab 3Fluorouracil 3Capecitabine 3venetoclax 2Rosuvastatin Calcium 2Prednisone 2Megestrol Acetate 2Leucovorin 2Drug Therapy 2Dexmedetomidine 2Dexamethasone 2Cyclophosphamide 2Bevacizumab 2Aspirin 2zanubrutinib 1xiaojin wan 1trastuzumab deruxtecan 1trametinib 1tocilizumab 1testosterone 17 beta-cypionate 1tenofovir alafenamide 1telitacicept 1taxane 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Not yet recruiting × Magnetic Resonance Spectroscopy × Clear all
NCT07462663 2026-05-13

SHAPE-ENDO

Hospital Universitari de Bellvitge

Phase 4 Not yet recruiting
82 enrolled
GynecologicOther

Endometrial Hyperplasia, Neoplasms, Obesity, Endometrial Neoplasms, Overweight

Data powered by HemOnc (CC BY 4.0) Colophon âš¡